Real-world study explores new drug for breast cancer

NCT ID NCT05851677

Recruiting now Disease control Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study is looking at how well a drug called Disitamab vedotin (RC48-ADC) works for breast cancer patients in real-world settings, outside of strict clinical trials. Researchers will track 45 patients to see how long they live without their cancer getting worse and what side effects occur. The goal is to understand the drug's true effectiveness and safety when used in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Disitamab vedotin (RC48-ADC)
What this could lead to: If successful, this could provide real-world evidence that Disitamab vedotin is a safe and effective treatment option for breast cancer patients.
What could go wrong: This is a small, observational study with only 45 participants, so results may not apply to all breast cancer patients. It is not a randomized controlled trial, so effectiveness is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Renji Hospital, School of Medicine, Shanghai Jiaotong University
RECRUITING

Shanghai, 200127, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.